On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

CRISPR Therapeutics CRSP is expected to report fourth ... whether it would be a prudent move to buy, sell, or hold the stock at present. In the past year, thestock has plunged 41% compared with ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

2025 Stock Picks. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of ...